Trudy C. Wu, MD

Trudy C. Wu, MD

Health Sciences Clinical Assistant Professor, Department of Radiation Oncology

Languages

English

Education

Internship

Transitional Year, Mount Carmel Health System, 2020

Degrees

MD, The Ohio State University College of Medicine, Columbus, OH, 2019
BS, The Ohio State University, Columbus, OH, 2014

Residency

Radiation Oncology, University of California, Los Angeles, Department of Radiation Oncology, 2024

Contact Information

Scientific Interests

Dr. Wu's primary research interest is in cholangiocarcinoma (CCA), a rare malignancy with approximately 8,000 new cases diagnosed annually in the United States. Despite its rarity, CCA is projected to become the fourth leading cause of cancer-related death by 2040. Her research interests span from investigating patterns of failure following curative-intent surgical resection in order to identify a role for adjuvant local therapy to improving transplant protocols. Dr. Wu is particularly passionate about optimizing outcomes after liver transplantation following neoadjuvant therapy, and firmly believes that liver transplantation offers CCA patients the most promising chance at a cure. She aims to improve these transplant protocols and ultimately, expand liver transplantation eligibility to those with recurrent intrahepatic disease.

Highlighted Publications

Wu TC, Luterstein E, Neilsen BK, Goldman JW, Garon EB, Lee JM, Felix C, Cao M, Tenn SE, Low DA, Kupelian PA, Steinberg ML, Lee P. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Mar 1;10(3):352-359. doi: 10.1001/jamaoncol.2023.6033. PMID: 38206614

Wu TC, Farrell MJ, Karimi-Mostowfi N, Chaballout BS, Akingbemi WO, Grogan T, Raldow AC “Evaluating the Impact of Race and Ethnicity on Health-Related Quality of Life Disparities in Patients with Esophageal Cancer: A SEER-MHOS National Database Study” Cancer Epidemiol Biomarkers Prev. 2023 Nov 28. doi: 10.1158/1055-9965.EPI-23-0789. Epub ahead of print. PMID: 38015776

Wu TC, Deng J, Chu F, Sadeghi S, Finn R, Agopian VG, Lee P, Raldow AC “A Single Center Experience Using Stereotactic Body Radiation Therapy (SBRT) on Orthotopic Liver Transplant Protocol for Unresectable Cholangiocarcinoma” HPB (Oxford). 2023 Dec 10:S1365-182X(23)02011-7. doi: 10.1016/j.hpb.2023.12.004. Epub ahead of print. PMID: 38142182

Wu TC, Smith CP, Li JS, Burton J, Jackson NJ, Tao R, Ludmir EB, Raldow AC. A Systematic Review and Meta-analysis of Pathologic Complete Response Rates for Patients with Unresectable Cholangiocarcinoma treated on Orthotopic Liver Transplant Protocols. J Surg Oncol. 2023 Nov 20. doi: 10.1002/jso.27511. Epub ahead of print. PMID: 37986552

Wu TC, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon EB, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG, Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow AC, Lee P. Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2023 Apr 4:S0360-3016(23)00325-5. doi: 10.1016/j.ijrobp.2023.03.069. Epub ahead of print. PMID: 37023987.